Prospective Phase III Evaluation of Fetal Fibronectin in a High Risk Population for the Prediction of Spontaneous Preterm Birth – 10Q Quant Study

Glenn Markenson, MD

Baystate Medical Center
759 Chestnut Street
Springfield, MA

The purpose of this study is to determine if quantitative analysis of fetal fibronectin can be used to advance prediction of spontaneous preterm birth.

  • Pregnant women from 16 weeks 0 days to 21 weeks, 6 days gestation
  • Maternal age 18 years or older
  • High risk for preterm birth
Laura Gebhardt: 413-794-2706
Joanne Montgomery: 413-794-3118